Frequent STAT5B mutations in γδ hepatosplenic T-cell lymphomas

Leukemia

Volumn 28, Issue 11, 2014, Pages 2244-2248

  Nicolae, A ^a   Xi, L ^a   Pittaluga, S ^a   Abdullaev, Z ^a   Pack, S D ^a   Chen, J ^a   Waldmann, T A ^a   Jaffe, E S ^a   Raffeld, M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LYMPHOCYTE ANTIGEN RECEPTOR; STAT5 PROTEIN; STAT5B PROTEIN, HUMAN;

ADULT; AGED; CHILD; FEMALE; GENETICS; HUMAN; LIVER; MALE; MIDDLE AGED; MUTATION; PATHOLOGY; SPLEEN; T CELL LYMPHOMA; YOUNG ADULT;

ADULT; AGED; CHILD; FEMALE; HUMANS; LIVER; LYMPHOMA, T-CELL; MALE; MIDDLE AGED; MUTATION; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; SPLEEN; STAT5 TRANSCRIPTION FACTOR; YOUNG ADULT;

EID: 85027954433     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.200     Document Type: Letter

References (16)

1. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues 4th edn. International Agency for Research on Cancer (IARC): Lyon, 2008.
2. Jonveaux P, Daniel MT, Martel V, Maarek O, Berger R. Isochromosome 7q and trisomy 8 are consistent primary, non-random chromosomal abnormalities associated with hepatosplenic T gamma/delta lymphoma. Leukemia 1996; 10: 1453–1455.
3. Travert M, Huang Y, de Leval L, Martin-Garcia N, Delfau-Larue MH, Berger F et al. Molecular features of hepatosplenic T-cell lymphoma unravels potential novel therapeutic targets. Blood 2012; 119: 5795–5806. DOI: 10.1182/blood-2011-12-396150
4. Heltemes-Harris LM, Farrar MA. The role of STAT5 in lymphocyte development and transformation. Curr Opin Immunol 2012; 24: 146–152. DOI: 10.1016/j.coi.2012.01.015
5. Oh HM, Yu CR, Golestaneh N, Amadi-Obi A, Lee YS, Eseonu A et al. STAT3 protein promotes T-cell survival and inhibits interleukin-2 production through up-regulation of Class O Forkhead transcription factors. J Biol Chem 2011; 286: 30888–30897. DOI: 10.1074/jbc.M111.253500
6. Mitchell TJ, John S. Signal transducer and activator of transcription (STAT) signalling and T-cell lymphomas. Immunology 2005; 114: 301–312. DOI: 10.1111/j.1365-2567.2005.02091.x
7. Jerez A, Clemente MJ, Makishima H, Koskela H, Leblanc F, Peng Ng K et al. STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia. Blood 2012; 120: 3048–3057. DOI: 10.1182/blood-2012-06-435297
8. Koskela HL, Eldfors S, Ellonen P, van Adrichem AJ, Kuusanmaki H, Andersson EI et al. Somatic STAT3 mutations in large granular lymphocytic leukemia. N Engl J Med 2012; 366: 1905–1913. DOI: 10.1056/NEJMoa1114885
9. Ohgami RS, Ma L, Merker JD, Martinez B, Zehnder JL, Arber DA. STAT3 mutations are frequent in CD30+ T-cell lymphomas and T-cell large granular lymphocytic leukemia. Leukemia 2013; 27: 2244–2247. DOI: 10.1038/leu.2013.104
10. Kiel MJ, Velusamy T, Rolland D, Sahasrabuddhe AA, Chung F, Bailey NG et al. Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia. Blood 2014; e-pub ahead of print 13 May 2014 doi:10.1182/blood-2014-03-559542. DOI: 10.1182/blood-2014-03-559542
11. Rajala HL, Eldfors S, Kuusanmaki H, van Adrichem AJ, Olson T, Lagstrom S et al. Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia. Blood 2013; 121: 4541–4550. DOI: 10.1182/blood-2012-12-474577
12. Kontro M, Kuusanmäki H, Eldfors S, Burmeister T, Andersson EI, Bruserud Ø et al. Novel activating STAT5B mutations as putative drivers of T-cell acute lymphoblastic leukemia. Leukemia 2014; e-pub ahead of print 27 February 2014 doi:10.1038/leu.2014.89. DOI: 10.1038/leu.2014.89
13. Sandberg Y, Almeida J, Gonzalez M, Lima M, Barcena P, Szczepanski T et al. TCRgammadelta+ large granular lymphocyte leukemias reflect the spectrum of normal antigen-selected TCRgammadelta+ T-cells. Leukemia 2006; 20: 505–513. DOI: 10.1038/sj.leu.2404112
14. Bessette K, Lang ML, Fava RA, Grundy M, Heinen J, Horne L et al. A Stat5b transgene is capable of inducing CD8+ lymphoblastic lymphoma in the absence of normal TCR/MHC signaling. Blood 2008; 111: 344–350. DOI: 10.1182/blood-2007-04-084707
15. Nelson EA, Walker SR, Weisberg E, Bar-Natan M, Barrett R, Gashin LB et al. The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors. Blood 2011; 117: 3421–3429. DOI: 10.1182/blood-2009-11-255232
16. Liu S, Walker SR, Nelson EA, Cerulli R, Xiang M, Toniolo PA et al. Targeting STAT5 in hematological malignancies through inhibition of the bromodomain and extra-terminal (BET) bromodomain protein BRD2. Mol Cancer Ther 2014; 13: 1194–1205. DOI: 10.1158/1535-7163.MCT-13-0341